Personalis, Inc. (NASDAQ:PSNL) announced that its board of directors appointed Richard Chen as president, effective March 13, 2026. Dr. Chen will assume the role in addition to his current positions as executive vice president of research and development and chief medical officer. The appointment follows a recommendation from Christopher Hall, the company’s chief executive officer, who previously served as president.
Dr. Chen, age 55, has served as executive vice president, R&D, since March 2023 and as chief medical officer since July 2021. He was previously senior vice president, R&D, from July 2021 to March 2023, and chief scientific officer from November 2011 to July 2021. Dr. Chen has also been a clinical faculty member at Stanford University School of Medicine since September 2011 and co-founded Ingenuity Systems, a genomic data software company, in August 1997. He holds a B.S. in computer science, an M.S. in medical informatics, and an M.D., all from Stanford University.
In connection with his appointment, Dr. Chen’s annual base salary will increase to $570,000, effective April 1, 2026. His target performance bonus will be raised to 70% of his annual base salary. On March 15, 2026, Dr. Chen will be granted an option to purchase 37,500 shares of Personalis common stock at an exercise price equal to the closing price on March 13, 2026. The stock options will vest in equal monthly installments over 36 months. He will also receive a restricted stock unit award for 6,250 shares, which will vest and settle in equal installments every six months, beginning on the six-month anniversary of the grant date, subject to his continued service.
These equity awards will be granted under the company’s 2019 Equity Incentive Plan.
All information is based on a statement from a recent SEC filing.
In other recent news, Personalis Inc. reported its financial results for the fourth quarter of 2025, revealing a mixed performance. The company exceeded earnings per share expectations with a result of -0.26, compared to the forecasted -0.3, representing a positive surprise of 13.33%. However, revenue came in below expectations at $17.3 million, missing the forecast of $17.55 million by 1.42%. In other developments, Richard Chen has been promoted to the role of president while continuing as chief medical officer, where he will oversee various company functions including research and development.
Analysts have also weighed in on Personalis, with Needham raising its price target to $12 from $10, maintaining a Buy rating due to recent reimbursement wins. Meanwhile, BTIG reaffirmed its $13 price target and Buy rating, highlighting the company’s expansion plans for its minimal residual disease (MRD) business. Personalis intends to double its direct sales force for the MRD segment, working alongside commercial partner Tempus. These developments reflect ongoing strategic initiatives and analyst confidence in the company’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.